<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673214</url>
  </required_header>
  <id_info>
    <org_study_id>R-2020-785-176</org_study_id>
    <nct_id>NCT04673214</nct_id>
  </id_info>
  <brief_title>Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment</brief_title>
  <official_title>Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilberto Cruz Arteaga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed for patients with mild COVID-19 phase, to demonstrate if there&#xD;
      is a modification in the clinical evolution greater than or equal to 25% in their symptoms,&#xD;
      implemented in two groups of patients under an early intervention treatment, a group ( A)&#xD;
      will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will&#xD;
      receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a&#xD;
      potential fatal disease generating a global public health problem. Person-to-person&#xD;
      transmission of COVID-19 infection led to the isolation of patients who subsequently received&#xD;
      a variety of treatments. Ivermectin treatment for safety is approved for human use by the FDA&#xD;
      in parasitic and skin infections. Studies report the therapeutic safety of Ivermectin in&#xD;
      humans with COVID-19, describing a 6.1-fold decrease in lethality compared to patients who&#xD;
      did not use Ivermectin (1.4 vs. 8.5%, p &lt;0.0001). In this sense, the WHO and PAHO encourage&#xD;
      the use of unproven therapies in the context of a randomized clinical trial (RCT).&#xD;
      Anticoagulants have reported up to 20% in the reduction of mortality (heparin), Ribaroxaban&#xD;
      is effective with the inhibition of PAR1 / PAR2 / PAR4 receptors through the blocking of&#xD;
      Factor Xa and the formation of thrombin, having anti-inflammatory effects, decreasing&#xD;
      arteriosclerosis and platelet aggregation. There is a Telemedicine working method implemented&#xD;
      by the OOAD of the North Federal District, which detects early signs and symptoms of possible&#xD;
      complications and offers an early intervention treatment policy for first-level care&#xD;
      beneficiaries. Under this method, a quasi-experimental study showed that there is a&#xD;
      modification in the frequency of recovered patients of 80-90% in patients diagnosed with&#xD;
      COVID-19 after an early intervention treatment with paracetamol, Ivermectin, Azithromycin,&#xD;
      Ribaroxaban in patients with COVID -19 from UMF 13 during the period of July-August 2020.&#xD;
      Therefore, it is necessary to carry out a randomized clinical trial to confirm this&#xD;
      assertion.&#xD;
&#xD;
      Objective: To evaluate the percentage of patients with a diagnosis of COVID-19 who modify&#xD;
      their clinical evolution under a comparative treatment of early intervention in beneficiaries&#xD;
      of the U.M.F 13 and U.M.F 20 of the I.M.S.S., during the period of December 2020-January&#xD;
      2021.&#xD;
&#xD;
      Material and Methods: A randomized, single-blind, prospective, longitudinal and open&#xD;
      experimental study in 62 patients with COVID-19 from UMF No. 13 and No. 20 from November to&#xD;
      December 2020. Including 31 patients in group A (Azithromycin / Ivermectin / Ribaroxaban /&#xD;
      Paracetamol) and 31 patients in group B (Azithromycin / Ribaroxaban / Paracetamol). With&#xD;
      inclusion criteria over 18 years of age, have type 2 diabetes mellitus, Systemic Arterial&#xD;
      Hypertension, Obesity or overweight, PCR confirmation of COVID-19. For the video call, the&#xD;
      Family Medicine Units have Electronic Equipment Installation for Internet use. Exclusion&#xD;
      criteria are patients with severe COVID-19 (they deserve immediate referral to second level&#xD;
      of care, hospital). Elimination criteria are Prior informed consent, medication is given&#xD;
      randomly to a COVID-19 patient, a follow-up video call will be made at home for 14 days,&#xD;
      recording sex, age, education, date of disease onset, taking laboratories (hematic biometry,&#xD;
      C-reactive protein, D-dimer, Ferritin, prothrombin time, thromboplastin time, lactic&#xD;
      dehydrogenase) taken at the onset of the disease, taking as an outcome variable the&#xD;
      modification of the clinical course (clinical symptoms such as headache, cough, fever,&#xD;
      conjunctivitis , myalgias, arthralgias, rhinorrhea, odynophagia, anosmia, chest pain,&#xD;
      dyspnea) when granting treatment in groups A and B.. Statistical differences will be&#xD;
      evaluated using the Mann-Whitney U test with a power of 90% and a type I error rate of 1% for&#xD;
      the variable of modification of the clinical course in treatment groups A and B. analysis&#xD;
      will be performed in SPSS version 21.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Actual">February 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of patients with COVID-19 will be integrated, a Group A taking the following medications: Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin tablets of 500 mg will take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, it will be every 24 hours for 2 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days and a Group B will take Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin tablets of 500 mg will take 1 single dose tablet on the first day and then half a tablet orally every 24 hours for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>For the conformation of the groups, random numbers generated by lottery will be used in which the patient will take a piece of paper as he arrives and will have the number of the group to which he will be assigned. With a type of block randomization, A (Azithromycin, paracetamol, Ivermectin, and Ribaroxaban) and B (paracetamol, Azithromycin, and Ribaroxaban).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.</measure>
    <time_frame>14 days</time_frame>
    <description>Statistical differences were evaluated using Student's t test for quantitative variables. In relation to the presence of the number of days with clinical symptoms of COVID-19 by double therapy vs. triple therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS</measure>
    <time_frame>14 days</time_frame>
    <description>Statistical differences between clinical evolution vs therapeutic failure by type of treatment were evaluated using Pearson's Chi-square test as categorical variables.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS</measure>
    <time_frame>14 days</time_frame>
    <description>Statistical differences were evaluated using Student's t test for quantitative variables. The average duration of days with clinical symptoms of COVID-19 under early intervention treatment by outcome in the improvement of the modification of the clinical evolution of symptoms vs. therapeutic failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Were Alive and Had COVID-19 Symptoms by Type of Therapy During a 14-day Follow-up</measure>
    <time_frame>14 days</time_frame>
    <description>Survival analysis. The time it takes for 50% of COVID-19 patients to improve symptoms during a 14-day follow-up with dual therapy vs. triple therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin / Ivermectin / Ribaroxaban / Paracetamol</intervention_name>
    <description>In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily</description>
    <arm_group_label>Triple therapy</arm_group_label>
    <other_name>with Ivermectin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin / Ribaroxaban / Paracetamol</intervention_name>
    <description>In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily</description>
    <arm_group_label>Double therapy</arm_group_label>
    <other_name>without Ivermectin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients Eligible for Family Medicine Unit No.20 and Family Medicine Unit No.13&#xD;
             belonging to the North DF of the IMSS.&#xD;
&#xD;
          -  Male and female patients&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients with compliance with the operational definition COVID-19 and confirmatory&#xD;
             test of P.C.R. positive within the first days of the illness (that are evaluated in&#xD;
             first level of medical attention).&#xD;
&#xD;
          -  Patients with comorbidities such as Type 2 Diabetes Mellitus, Systemic Arterial&#xD;
             Hypertension, Overweight or Obesity.&#xD;
&#xD;
          -  That they agree to sign an informed consent&#xD;
&#xD;
             - Related to Video Call:&#xD;
&#xD;
          -  That the Family Medicine Unit No.20 and the Family Medicine Unit No.13 belonging to&#xD;
             the North DF of the IMSS have the Installation of Electronic Equipment for Internet&#xD;
             use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe COVID-19 patients (Ameriten sent immediately to second level of care, hospital)&#xD;
             Patients with any Personal Pathological History of Hematological Diseases. • Patients&#xD;
             allergic to macrolides (Azithromycin) and Ivermectin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GILBERTO CR ARTEAGA, specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEXICAN SOCIAL SECURITY INSTITUTE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alma Italia Guerrero Martinez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>02000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.ijantimicag.2020.105949</url>
    <description>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/results/NCT04343092?term=NCT04343092&amp;draw=2&amp;rank=1&amp;view=results</url>
    <description>Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management</description>
  </link>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Becattini C, Pace U, Rondelli F, Delrio P, Ceccarelli G, Boncompagni M, Graziosi L, Visonà A, Chiari D, Avruscio G, Frasson S, Gussoni G, Biancafarina A, Camporese G, Donini A, Bucci AF, Agnelli G. Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. Eur J Intern Med. 2020 Feb;72:53-59. doi: 10.1016/j.ejim.2019.11.015. Epub 2019 Dec 7.</citation>
    <PMID>31818628</PMID>
  </reference>
  <reference>
    <citation>Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.</citation>
    <PMID>30786186</PMID>
  </reference>
  <reference>
    <citation>Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM. Receptors of the PAR family as a link between blood coagulation and inflammation. Biochemistry (Mosc). 2002 Jan;67(1):65-74. Review.</citation>
    <PMID>11841341</PMID>
  </reference>
  <reference>
    <citation>Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May. Review.</citation>
    <PMID>32322397</PMID>
  </reference>
  <reference>
    <citation>Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. Review. Erratum in: Clin Pharmacol Ther. 2021 May;109(5):1362.</citation>
    <PMID>32438446</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <results_first_submitted>March 8, 2021</results_first_submitted>
  <results_first_submitted_qc>August 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2021</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Gilberto Cruz Arteaga</investigator_full_name>
    <investigator_title>Clinical Coordinator of Health Education and Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04673214/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04673214/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment begins on December 16, 2020 in the Family Medicine Unit No.13 and in the Family Medicine Unit No.20 of the Mexican Institute of Social Security.</recruitment_details>
      <pre_assignment_details>There were no excluded patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Triple Therapy</title>
          <description>65 triple therapy patients received the assigned intervention with Azithromycin tablets 500 mg 1 tablet in a single dose the first day and then half a tablet (250 mg) orally every 24 4 days, ivermectin tablets of 200 mcg calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days and Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
        <group group_id="P2">
          <title>Double Therapy</title>
          <description>46 double therapy patients received the assigned intervention with Azithromycin 500 mg tablets 1 single dose tablet on the first day and then half a tablet (250 mg) orally every 24 4 days and rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days with Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lost to Follow up</title>
              <participants_list>
                <participants group_id="P1" count="2">These patients were discontinued, given in the first days of their follow-up by video call, they presented major symptoms such as dyspnea of movement, dyspnea at rest, and chest pain; Following the protocol's follow-up criteria, patients were informed of their clinical care at the hospital level immediately, and the protocol was no longer followed. Subsequently, when capturing information in the data analysis, the clinical status of the patients is searched, registering their death.</participants>
                <participants group_id="P2" count="1">This patient was stopped being followed up in the first days of his follow-up by video call. He presented major symptoms such as dyspnea of movement, dyspnea at rest, and chest pain; With the follow-up criteria of the protocol, the patient was informed of their clinical care at the hospital level immediately, and the protocol was no longer followed. Subsequently, when capturing information in the data analysis, the clinical status of the patient is searched, registering death.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Double Therapy</title>
          <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
        <group group_id="B2">
          <title>Triple Therapy</title>
          <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS &lt;80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS&gt; 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mestizo Mexicans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>21-30 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>31-40 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>41-50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>51-60 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>61-70 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 71 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Occupation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Part time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Full time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Housewife</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pensioner</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Civil Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Widower</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Free Union</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Divorced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Primary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Preparatory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Technical career</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Degree</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.</title>
        <description>Statistical differences were evaluated using Student's t test for quantitative variables. In relation to the presence of the number of days with clinical symptoms of COVID-19 by double therapy vs. triple therapy.</description>
        <time_frame>14 days</time_frame>
        <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DOUBLE THERAPY</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
          <group group_id="O2">
            <title>TRIPLE THERAPY</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS &lt;80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS&gt; 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.</title>
          <description>Statistical differences were evaluated using Student's t test for quantitative variables. In relation to the presence of the number of days with clinical symptoms of COVID-19 by double therapy vs. triple therapy.</description>
          <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="5.4"/>
                    <measurement group_id="O2" value="7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="3.4"/>
                    <measurement group_id="O2" value="2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5.2"/>
                    <measurement group_id="O2" value="5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="4.8"/>
                    <measurement group_id="O2" value="3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Odynophagia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="4.8"/>
                    <measurement group_id="O2" value="5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="4"/>
                    <measurement group_id="O2" value="1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5.6"/>
                    <measurement group_id="O2" value="5" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anosmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5.8"/>
                    <measurement group_id="O2" value="6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="4.1"/>
                    <measurement group_id="O2" value="1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5.6"/>
                    <measurement group_id="O2" value="4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea of movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="4.1"/>
                    <measurement group_id="O2" value="2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysnea at rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3.3"/>
                    <measurement group_id="O2" value="2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3.1"/>
                    <measurement group_id="O2" value="5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2.7"/>
                    <measurement group_id="O2" value="3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>treatment start day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.9"/>
                    <measurement group_id="O2" value="4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: There will be no modification in the clinical evolution ≥ 25% of patients diagnosed with COVID-19 under an early intervention treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol for 14 days followed by video call from U.M.F 13 and U.M.F 20 from I.M.S.S., during the period of December 2020- February 2021, with a power of 90%, type I error rate 1% and loss to follow-up 20%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis for the modification in the clinical evolution of the conjunctivitis sign in patients diagnosed with COVID-19 under early intervention treatment with Azithromycin / Ribaroxaban / Paracetamol for 14 days followed by video call is rejected.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>Presence of a p &lt;0.05 as significant in the comparison of treatment with clinical symptoms</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a difference of 2 days in the modification of the clinical course (symptoms of fever, cough, headache, myalgia, odynophagia, anosmia, rhinorrhea, arthralgia, chest pain, dyspnea, conjunctivitis) of patients diagnosed with COVID-19 in early intervention treatment vs. therapeutic failure, for 14 days followed by video call, with a power of 90%, a type I error rate of 1% and a loss to follow-up of the twenty%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is rejected with a difference of 2 days in the modification of the clinical evolution (symptoms of fever, cough, headache, myalgia, odynophagia, anosmia, rhinorrhea, arthralgia, chest pain, dyspnea, conjunctivitis) of patients diagnosed with COVID -19 in early intervention treatment. vs. therapeutic failure, for 14 days followed by video call, with a power of 90%, a type I error rate of 1% and a loss to follow-up of 20%</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS</title>
        <description>Statistical differences between clinical evolution vs therapeutic failure by type of treatment were evaluated using Pearson's Chi-square test as categorical variables.</description>
        <time_frame>14 days</time_frame>
        <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Double Therapy</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
          <group group_id="O2">
            <title>Triple Therapy</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS &lt;80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS&gt; 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
        </group_list>
        <measure>
          <title>Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS</title>
          <description>Statistical differences between clinical evolution vs therapeutic failure by type of treatment were evaluated using Pearson's Chi-square test as categorical variables.</description>
          <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with Improvement in Clinical Evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with Therapeutic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a difference in the percentage of effectiveness in the clinical modification and therapeutic failure of patients diagnosed with COVID-19 under treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call, with a power of 90%, a type I error rate of 1% and a loss to follow-up of 20%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Assuming a difference in the percentage of effectiveness in the clinical modification and therapeutic failure of patients diagnosed with the outcome of improvement in the Modification of the clinical evolution of the symptoms of patients with COVID-19 using double therapy was reported 95.7% (n = 44) Vs. triple therapy 90.8% (n = 59) and therapeutic failure 4.3% (n = 2) vs. 9.2% (n = 6), respectively.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>Presence of a p &lt;0.05 as significant in the comparison of treatment with clinical symptoms the clinical modification and therapeutic failure of patients diagnosed with COVID-19</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS</title>
        <description>Statistical differences were evaluated using Student's t test for quantitative variables. The average duration of days with clinical symptoms of COVID-19 under early intervention treatment by outcome in the improvement of the modification of the clinical evolution of symptoms vs. therapeutic failure.</description>
        <time_frame>14 days</time_frame>
        <population>Assuming a difference in days of effectiveness in clinical modification and therapeutic failure of patients diagnosed with COVID-19 in treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call, with a potency 90%, a Type I error rate of 1%, and a loss to follow-up of 20%</population>
        <group_list>
          <group group_id="O1">
            <title>Modification of Evolution Clinic</title>
            <description>Improvement of the clinical health conditions of symptoms such as headache, cough, fever, conjunctivitis, myalgia, arthralgia, rhinorrhea, odynophagia, anosmia, chest pain, dyspnea after the administration of the dual therapy of Azithromycin / Ribaroxaban / Paracetamol and the Azithromycin / Ivermectin / Ribaroxaban / Paracetamol triple therapy in patients with mild Covid-19 clinical phase performed by video call monitoring lasting 15-20 minutes for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Therapeutic Failure</title>
            <description>Lack of efficacy after the administration of Azithromycin / Ribaroxaban / Paracetamol dual therapy and Azithromycin / Ivermectin / Ribaroxaban / Paracetamol triple therapy in the registry of clinical health conditions of symptoms such as headache, cough, fever, conjunctivitis, myalgia, arthralgia , rhinorrhea, odynophagia, anosmia, chest pain, dyspnea, of patients with mild clinical phase Covid-19 performed by monitoring with a duration of 15-20 minutes during 14 days of follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS</title>
          <description>Statistical differences were evaluated using Student's t test for quantitative variables. The average duration of days with clinical symptoms of COVID-19 under early intervention treatment by outcome in the improvement of the modification of the clinical evolution of symptoms vs. therapeutic failure.</description>
          <population>Assuming a difference in days of effectiveness in clinical modification and therapeutic failure of patients diagnosed with COVID-19 in treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call, with a potency 90%, a Type I error rate of 1%, and a loss to follow-up of 20%</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="5.6"/>
                    <measurement group_id="O2" value="4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="3.3"/>
                    <measurement group_id="O2" value="1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5"/>
                    <measurement group_id="O2" value="2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4.6"/>
                    <measurement group_id="O2" value="1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Odynophagia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5.2"/>
                    <measurement group_id="O2" value="2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="3.2"/>
                    <measurement group_id="O2" value="1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5.4"/>
                    <measurement group_id="O2" value="5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anosmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="6"/>
                    <measurement group_id="O2" value="2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3.6"/>
                    <measurement group_id="O2" value="1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="5.2"/>
                    <measurement group_id="O2" value="1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea of movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="4.1"/>
                    <measurement group_id="O2" value="3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea at Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3.5"/>
                    <measurement group_id="O2" value="3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3.3"/>
                    <measurement group_id="O2" value="2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2.6"/>
                    <measurement group_id="O2" value="2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a difference in days of effectiveness in clinical modification and therapeutic failure of patients diagnosed with COVID-19 in treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call, with a potency 90%, a Type I error rate of 1%, and a loss to follow-up of 20%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is rejected with a mean duration of 2 days with clinical symptoms of COVID-19 in early intervention treatment as a result of improving the modification of the clinical evolution of symptoms vs therapeutic failure.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Were Alive and Had COVID-19 Symptoms by Type of Therapy During a 14-day Follow-up</title>
        <description>Survival analysis. The time it takes for 50% of COVID-19 patients to improve symptoms during a 14-day follow-up with dual therapy vs. triple therapy</description>
        <time_frame>14 days</time_frame>
        <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Therapy</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
          <group group_id="O2">
            <title>Triple Therapy</title>
            <description>The following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS &lt;80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS&gt; 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Alive and Had COVID-19 Symptoms by Type of Therapy During a 14-day Follow-up</title>
          <description>Survival analysis. The time it takes for 50% of COVID-19 patients to improve symptoms during a 14-day follow-up with dual therapy vs. triple therapy</description>
          <population>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cought</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Odynophagia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anosmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea of movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea at rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Gehan) statistical test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected was 14 days.</time_frame>
      <desc>No presence of serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Dual Therapy Adverse Event</title>
          <description>Record of adverse reactions of Blood and lymphatic system disorders, Heartdisorders, Ear and labyrinth disorders,Gastrointestinal disorders and Musculoskeletal and connective tissue disorders with the following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
        <group group_id="E2">
          <title>Adverse Event Triple Therapy</title>
          <description>Record of adverse reactions of Blood and lymphatic system disorders, Heartdisorders, Ear and labyrinth disorders,Gastrointestinal disorders and Musculoskeletal and connective tissue disorders with the following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS &lt;80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS&gt; 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <description>Symptom presented in patients without causing without requiring immediate medical attention or subsequent clinical follow-up.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>Symptom presented in patients without causing without requiring immediate medical attention or subsequent clinical follow-up.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <description>Symptom presented in patients without causing without requiring immediate medical attention or subsequent clinical follow-up.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Symptom presented in patients without causing without requiring immediate medical attention or subsequent clinical follow-up.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <description>Symptom presented in patients without causing without requiring immediate medical attention or subsequent clinical follow-up</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="46"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. GILBERTO CRUZ ARTEAGA</name_or_title>
      <organization>MEXICAN SOCIAL SECURITY INSTITUTE</organization>
      <phone>55 87 44 22 ext 15320</phone>
      <email>gilberto.cruz@imss.gob.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

